Swedish Orphan Biovitrum AB

SOBI

SE0000872095

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 15:41:16 23/01/2026 +04			5-day change	1st Jan Change
339.60 ^SEK	+1.92%		+2.41%	+2.04%

10:37am	Berenberg Raises Price Target for Sobi to 420 Kronor (405), Reiterates Buy - BN	FW
01-19	SEB Raises Price Target for Sobi to 500 Kronor (400), Reiterates Buy	FW

Sobi to Buy Arthrosi Therapeutics for Up to $1.5 Billion

Published on 12/14/2025 at 02:34 pm +04

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Swedish Orphan Biovitrum AB

10:37am	Berenberg Raises Price Target for Sobi to 420 Kronor (405), Reiterates Buy - BN	FW
01-19	SEB Raises Price Target for Sobi to 500 Kronor (400), Reiterates Buy	FW
01-16	Sobi's Rare Kidney Diseases Drug Lands Approval in Europe	MT
01-16	Sobi Receives European Commission Approval for Aspaveli® (Pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN	CI
01-16	Sobi's Aspaveli Receives EU Approval for Treatment of Two Kidney Diseases	FW
01-16	Sobi's Aspaveli Approved in the EU for Two Kidney Diseases	FW
01-15	Sobi 2025 revenue, EBITA margin exceed outlook	RE
01-15	Strong Sales Prompt Sobi to Issue Positive Profit Warning for 2025 (Update 2)	FW
01-15	Strong Sales Prompt Sobi to Issue Upward Profit Warning for 2025 (Update)	FW
01-15	Strong Sales Prompt Sobi to Issue Positive Earnings Warning for 2025	FW
01-15	Sobi's Revenues and Adjusted EBITA Margin for 2025 Exceeded Expectations	FW
01-15	Sobi Issues Upward Profit Warning for 2025	FW
01-14	Pareto Raises Price Target for Sobi and Reiterates Buy Recommendation	FW
01-14	Pareto Securities Raises Target Price for Sobi to 385 Kronor (360), Reiterates Buy Recommendation	FW
01-14	Swedish Orphan Biovitrum AB Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM
01-13	Danske Bank Raises Target Price for Sobi to 388 Kronor (377), Reiterates Buy - BN	FW
01-08	ABG Sundal Collier Upgrades Swedish Orphan Biovitrum to Buy, Boosts PT	MT
01-08	Sobi Rises After ABG Upgrades to Buy on Positive Study Data - BN	FW
01-08	ABG Sundal Collier Upgrades Sobi to Buy (Hold), Raises Target Price to 450 Kronor (290) - BN	FW
01-08	Stockholm Bullets - Opens Lower, Saab Rises on Trump's Call for Increased Investments	FW
01-08	Sobi to Further Develop Gamifant Following Topline Data from Phase 2a Study	FW
01-08	Sobi Partnership to Advance Gamifant as Interferon-gamma-driven Sepsis Treatment	MT
01-07	Sobi to advance Gamifant® (emapalumab) in IDS based on Embrace topline data	RE
01-07	Sobi Announces to Advance Gamifant in Interferon-Gamma-Driven Sepsis Based on EMBRACE Topline Data	CI
01-07	Barclays Raises Sobi Target Price to 395 Kronor (from 350), Reiterates Overweight - BN	FW

Chart Swedish Orphan Biovitrum AB

Duration

Period

SOBI: Dynamic Chart

Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.

Employees

1,890

Sector

Pharmaceuticals

Calendar

02-05 - Q4 2025 Earnings Release

More about the company